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OBJECTIVES The goal of this study was to identify genes upregulated in the heart in human patients with
hypertrophic cardiomyopathy (HCM).
BACKGROUND Hypertrophic cardiomyopathy is a genetic disease caused by mutations in contractile
sarcomeric proteins. The molecular basis of diverse clinical and pathologic phenotypes in
HCM remains unknown.
METHODS We performed polymerase chain reaction-select complementary DNA subtraction between
normal hearts and hearts with HCM and screened subtracted libraries by Southern blotting.
We sequenced the differentially expressed clones and performed Northern blotting to detect
increased expression levels.
RESULTS We screened 288 independent clones, and 76 clones had less than twofold increase in the
signal intensity and were considered upregulated. Sequence analysis identified 36 genes
including those encoding the markers of pressure overload-induced (“secondary”) cardiac
hypertrophy, cytoskeletal proteins, protein synthesis, redox system, ion channels and those
with unknown function. Northern blotting confirmed increased expression of skeletal muscle
alpha-actin (ACTA1), myosin light chain 2a (MLC2a), GTP-binding protein Gs-alpha
subunit (GNAS1), NADH ubiquinone oxidoreductase (NDUFB10), voltage-dependent
anion channel 1 (VDAC1), four-and-a-half LIM domain protein 1 (FHL1) (also known as
SLIM1), sarcosin (SARCOSIN) and heat shock 70kD protein 8 (HSPA8) by less than
twofold. Expression levels of ACTA1, MLC2a and GNAS1 were increased in six additional
and FHL1 in four additional hearts with HCM.
CONCLUSIONS A diverse array of genes is upregulated in the heart in human patients with HCM, which
could account for the diversity of clinical and pathologic phenotypes. Markers of secondary
hypertrophy are also upregulated, suggesting commonality of pathways involved in HCM and
the acquired forms of cardiac hypertrophy. Elucidation of the role of differentially expressed
genes in HCM could provide for new therapeutic targets. (J Am Coll Cardiol 2001;38:
1175–80) © 2001 by the American College of Cardiology
Hypertrophic cardiomyopathy (HCM) is a genetic disease
caused by mutations in the contractile sarcomeric proteins
(1). Hypertrophic cardiomyopathy is diagnosed clinically by
the presence of unexplained left ventricular hypertrophy and
pathologically by myocyte hypertrophy, disarray and inter-
stitial fibrosis (2). While the causality of mutant contractile
proteins in the pathogenesis of HCM is well established,
the molecular bases of diverse cardiac phenotypes in HCM
remain unknown.
We and others have proposed cardiac hypertrophy in
HCM is a “compensatory” phenotype due to increased
cardiac myocyte stress or altered Ca12 sensitivity of the
contractile apparatus imparted by the mutant contractile
proteins (3). Accordingly, increased myocyte stress leads to
expression of a variety of cardiac genes that activate the
transcription machinery leading to hypertrophy and other
phenotypes of HCM. Thus, the pathogenesis of hypertro-
phy, a common programmed response of the myocardium
to any form of stress, whether caused by a genetic defect or
by an acquired condition, involves common pathways.
Similarly, pathogenesis of diverse cardiac phenotypes also
results from upregulation of expression of a variety of genes
in response to the primary impetus provided by the mutant
contractile protein (3). To identify genes that are upregu-
lated in the heart in HCM, as the initial step for delineating
their role in induction of cardiac phenotypes, we performed
subtraction hybridization between normal hearts and hearts
with HCM followed by Northern blotting to confirm
upregulation of expression of the differentially expressed
genes in HCM.
METHODS
Subtraction hybridization and differential screening.
Each patient signed an informed consent, and the institu-
tional review board approved the protocols. Subtraction
hybridization was performed between two messenger ribo-
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nucleic acid (mRNA) pools extracted from a heart with
HCM and a normal heart, using a polymerase chain
reaction (PCR)-select complementary deoxyribonucleic acid
(cDNA) subtraction kit (CLONETECH, Palo Alto, Cal-
ifornia). In brief, left ventricular septal tissue was obtained
by myomectomy from a patient who had a long-standing
history of symptomatic HCM with left ventricular outflow
tract obstruction. A corresponding segment of the interven-
tricular septum was excised from an age- and gender-
matched normal donor heart that was not used for cardiac
transplantation. Tissues were frozen in liquid nitrogen and
stored at 2135°C until mRNA extraction. Total RNA and
poly A1 RNA were extracted from hearts with HCM and
control hearts side-by-side using the same reagents and
protocols and quantified by measuring absorption at
260 nm. To select genes that were differentially expressed in
the heart in HCM, 2 mg of polyA1 mRNAs extracted were
used to generate subtraction cDNA libraries. The cDNA
library generated from the normal heart was subtracted from
that of the heart with HCM (forward subtraction) through
two sets of hybridization, which resulted in a library
enriched for genes that were upregulated in the heart with
HCM. A reverse subtraction cDNA library was generated
by subtracting the cDNA library generated from the heart
with HCM from that of the normal heart. To reduce the
background, two rounds of suppression PCR were per-
formed to amplify the differentially expressed genes. The
enriched cDNA library was subcloned into a T/A cloning
plasmid vector, and the resulting products were transformed
into Escherichia coli and plated on agar plates.
To confirm that the subtracted clones represented differ-
entially expressed genes and to reduce the number of false
positives, colonies were initially screened by PCR-select
differential screening (CLONETECH). In brief, the cloned
inserts were amplified by PCR using flanking primers, and
288 randomly selected clones in the forward-subtracted
cDNA library were arrayed on three sets of 96-spot dot blot
membranes in duplicates for subsequent hybridization.
Probes were prepared by PCR amplification of the forward
and reverse subtraction cDNA libraries, restriction enzyme
digestion to remove the adapter sequences in order to reduce
the background and radiolabeling with [32P] dCTP a
specific activity of more than 109 cpm/mg. Each set of
membranes was hybridized either with forward or reverse
subtracted probe in ExpressHyb solution (CLONE-
TECH). After washing in high stringency conditions, the
membranes were exposed to X-ray films in the presence of
intensifying screens for 24 h.
Sequencing. Differentially expressed clones were se-
quenced using Big Dye Terminator Cycle Sequencing
Ready Reaction Kit on an ABI Genetic Analyzer 310 (PE
Biosystem, Foster City, California). Sequences were ana-
lyzed using BLAST search of gene bank database.
Northern blotting. To confirm differential expression of
the putative candidate genes in HCM, Northern blotting
was performed on mRNA extracts from hearts with HCM
and control hearts. In brief, 10 mg aliquots of total RNA
extracts were loaded onto a formaldehyde-agarose gel,
subjected to electrophoresis and were transferred to a nylon
membrane (Bio-Rad Laboratories, Cambridge, Massachu-
setts). The forward-subtracted cDNA probes were radiola-
Figure 1. Subtracted clones dot blotted at 96-spot membranes. Membranes hybridized with radiolabeled forward and reverse subtracted complementary
deoxyribonucleic acid libraries. Differentially expressed genes, identified by a twofold increase in signal intensity in the membrane hybridized with the
forward subtraction probes, are shown by arrows. Clones hybridized with the reverse subtraction probes are considered background.
Abbreviations and Acronyms
ACTA1 5 skeletal muscle alpha-actin
cDNA 5 complementary deoxyribonucleic acid
FHL1 5 four-and-a-half LIM domain protein 1
GNAS1 5 guanosine 59-triphosphate (GTP)-
binding protein Gs-alpha subunit
HCM 5 hypertrophic cardiomyopathy
HSPA8 5 heat shock 70kD protein 8
MLC2a 5 myosin light chain 2A
mRNA 5 messenger ribonucleic acid
NDUFB10 5 reduced nicotinamide adenine
dinucleotide ubiquinone oxidoreductase
PCR 5 polymerase chain reaction
SARCOSIN 5 sarcosin
VDAC1 5 voltage-dependent anion channel 1
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beled with [32P] dCTP and hybridized to mRNAs on the
membranes in the presence of Denhardt’s reagent (0.1%
ficol, 0.1% polyvinylpyrrolidone, 0.1% bovine serum albu-
min, 100 mg/ml of denatured fragmented salmon sperm
DNA) in hybridization solution (6 3 sodium chloride-sodium
citrate, 0.5% sodium dodecylsulfate). After washing, the mem-
brane was exposed to an X-ray film for 24 to 48 h.
To determine whether the differentially expressed clones
were also upregulated in additional hearts with HCM,
Northern blotting was performed on mRNA extracts from
six additional hearts with HCM and two control hearts.
RESULTS
Genes upregulated in HCM. A total of 288 clones from
the subtracted library were screened by duplicate dot-blot
hybridization. A twofold or greater difference in the inten-
sity of signals detected from colonies hybridized with the
forward and reverse-subtraction probes (forward less than
reverse) was considered evidence of differential expression.
We identified 76 differentially expressed clones (Fig. 1) that
were sequenced. Blast analyses of the sequences identified
36 differentially expressed genes (Table 1) that code for a
diverse array of proteins with a variety of functions.
Northern blot analyses. Northern blot analyses were per-
formed to compare expression of skeletal muscle alpha-actin
(ACTA1), myosin light chain 2a (MLC2a), guanosine 59-
triphosphate (GTP)-binding protein Gs-alpha subunit
(GNAS1), reduced nicotinamide adenine dinucleotide ubiqui-
none oxidoreductase (NDUFB10), voltage-dependent anion
channel 1 (VDAC1), four-and-a-half LIM domain protein 1
Table 1. Differentially Expressed Genes in the Heart in HCM
Gene Symbol Accession # Locus # of Clone
Sarcomeric
Skeletal muscle a-actin ACTA1 J00068 1q42.13–q42.2 12
Myosin light chain 2a LOC58498 M94547 7p11.21–p11.2 7
Myosin light chain 2v MYL2v AF020768 12q23–q24.3 7
b-myosin heavy chain MYL7 M58018 14q2 3
a-myosin heavy chain MYH6 D00943 14q2 2
Skeletal fast myosin light chain 2 MLC2B M21812 ? 1
Myosin, light chain 3, alkali MYL3 M24122 3p21.3–p21.2 1
Sarcosin SARCOSIN AF056929 ? 1
Cytoskeletal
Four-and-a-half LIM protein 1 FHL1 U29538 Xq26 2
SLIMMER SLIMMER AF063002 Xq26 2
Skeletal muscle a 2 actinin ACTN2 M86406 1q42–q43 2
Nebulin-related protein NRAP U96486 10q24–q26 1
Desmin DES M63391 2q35 1
Protein synthesis
Transcription elongation fac 1a1 EEF1A1 X03558 6q14 4
A1U-rich element RNA binding factor HNRPDL D89678 4q13–21 2
Mitochondrial ribosomal RNA MTRNR1 S64650 mitochondrion 2
Mitochondrial ribosomal RNA 16S rRNA X93334 mitochondrion 1
Ribosomal protein S4X RPS4X M58458 Xq13.1 1
Ribosomal protein L31 RPL31 X15940 2 1
Ribosomal protein L24 RPL24 M94314 3q 1
Redox system
NADH ubiquinone oxidoreductase NDUFB10 AF088991 16 3
Ubiquinol-cytochrome c reductase core I UQCRC1 D26485 3p21.3 3
NADH dehydrogenase Fe-S protein 1 NDUFS1 X61100 2q33–q34 1
Ion channels
Voltage-dependent anion channel 1 VDAC1 L06132 5q31 1
Na1/H1 exchanger isoform 1 SLC9A1 S68616 1p36.1–p35 1
Solute carrier family 25, Member 3-1a SLC25A3 X77337 12q23 1
Extracellular matrix
a-1 (I) chain of procollagen type I COL1A1 AF017178 17q21.3–q22 1
Intracellular signal transduction
GTP-binding protein Gs a subunit GNAS1 X07036 20q13.2–q13.3 1
Others and unknowns
Heat shock 70kD protein 8 HSPA8 Y00371 11q23.3–q25 2
Smooth muscle myosin light chain 2 MYRL2 J02854 20 2
Nonsarcomeric MLC-regulatory MLCB X54304 18 2
B-type natriuretic peptide precursor BNNP M25296 1p36.2 1
Myoglobin gene MB X00372 22q13.1 1
HSPC040 (CGI-129) LOC51660 AF151887 6 1
Chromosome 1 open reading frame 8 C1ORF8 AF047439 1p36–p31 1
HCM 5 hypertrophic cardiomyopathy.
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(FHL1) (also known as SLIM1), sarcosin (SARCOSIN) and
heat shock 70kD protein 8 (HSPA8) between hearts with
HCM and control hearts. The results, shown in Figure 2,
confirmed upregulation of expression of ACTA1 (fourfold),
MLC2a (fivefold), GNAS1 (threefold), NDUFB10 (eightfold),
VDAC1 (twofold), FHL1 (twofold), SARCOSIN (twofold)
and HSPA8 (ninefold).
Expression levels of ACTA1, GNAS1, MLC2a and FHL1
genes were determined by Northern blotting in six addi-
tional left ventricular tissues from patients with HCM and
two normal hearts. The results are shown in Figure 3. As
shown, expression levels of ACTA1, GNAS1 and MLC2a
were increased in all six hearts by less than twofold, while
expression levels of FHL1 were increased by more than
twofold in four hearts.
DISCUSSION
A diverse array of genes encoding for proteins with variety
of functions, including markers of cardiac hypertrophy due
to pressure overload (secondary hypertrophy), is upregulated
in the human heart in HCM. The diversity of molecular
phenotype in HCM is in accord with the diversity of
pathologic and clinical phenotypes that encompass not only
Figure 2. Northern blots showing upregulation of expression of a selected differentially expressed gene identified by subtraction hybridization: the upper
panels shows blots representing expression of ACTA1, MLC2a, GNAS1, NDUFB10, HSPA8, VDAC1, FHL1 and SARCOSIN in hearts with
hypertrophic cardiomyopathy (H) and normal control (N) hearts. The lower panels show the corresponding agarose gels photographs showing 28 S and
18 S ribonucleic acids. ACTA1 5 skeletal muscle alpha-actin; FHL1 5 four-and-a-half LIM domain protein 1; GNAS1 5 GTP-binding protein
Gs-alpha subunit; HSPA8 5 heat shock 70kD protein 8; MLC2a 5 myosin light chain 2a; NDUFB10 5 reduced nicotinamide adenine dinucleotide
ubiquinone oxidoreductase; VDAC1 5 voltage-dependent anion channel 1.
Figure 3. Northern blots showing the expression of four differentially expressed genes in the left ventricular tissues of six additional patients with
hypertrophic cardiomyopathy (HCM). Lanes 1 and 2 represent the left ventricular samples obtained from normal hearts (donor hearts not used for
transplantation). Lanes 3 through 8 represent the left ventricular tissues obtained from patients with HCM. Expression levels of skeletal muscle alpha-actin
(A), myosin light chain 2A (B) and GTP-binding protein Gs-alpha subunit (C) were increased in all hearts with HCM, as compared with the control
hearts. Expression levels of four-and-a-half LIM domain protein 1 (D) were increased by less than twofold in 4 out of 6 hearts with HCM.
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myocyte hypertrophy and disarray but also interstitial fibro-
sis, thickening of the media of intramural coronary arteries
and arrhythmias (2). Increased expression of the markers of
“secondary” cardiac hypertrophy supports the hypothesis
that hypertrophy in HCM is also a “secondary” phenotype
(3), and common pathways are involved in the induction of
cardiac hypertrophy in genetic and nongenetic forms.
We have confirmed increased expression of selected
differentially expressed genes (eight genes) by Northern
blotting in the myomectomy sample that was used for
subtraction subsequently and subsequently for four genes in
multiple hearts with HCM, further validating the observed
results. We used PCR-select cDNA subtraction hybridiza-
tion, which is considered a robust technique for identifica-
tion of differentially expressed genes (4,5). Unlike microar-
ray DNA chips, which are restricted to known sequences
and are subject to bias for the selection of putative genes,
subtraction hybridization affords the opportunity to screen
all differentially expressed genes without a selection bias or
a priori knowledge of their sequences. However, it is a
tedious method, and, in each set of subtraction experiments,
a fraction of total differentially expressed genes are identi-
fied, and the yield decreases with each additional subtrac-
tion. We performed three sets of colony screening from a
single cDNA subtraction experiment and selected genes
that showed at least a twofold increase in the expression
levels. Therefore, the total number of differentially ex-
pressed genes in the heart in HCM could be greater. In
addition, expression of many genes could be decreased in
HCM, and, since we did not screen the reverse subtracted
library, they were not detected. Furthermore, cDNA sub-
traction hybridization detects gene expression at the mRNA
stage, which may not correspond to protein expression.
Moreover, expression profiling detects only expression of
the genes and not the activity of their proteins, which, for
many proteins, such as the intracellular signaling kinases, is
the primary determinant of protein function. Therefore, it
not surprising that upregulation of expression of intracellu-
lar signaling kinases, which play fundamental roles in
induction of acquired forms of cardiac hypertrophy (6) and,
likewise, are expected to modulate cardiac hypertrophy in
HCM, were not detected. Furthermore, expression profiling
is an initial step that provides a basis for future studies to
delineate the role of differentially expressed genes in the
pathogenesis of cardiac phenotype.
A variety of genes including those encoding for contrac-
tile sarcomeric proteins, cytoskeletal proteins, ion channels,
intracellular signal tranducers, protein maintaining the re-
dox state of the myocardium, along with transcriptional and
translation machinery were upregulated in HCM. The most
common upregulated genes were the markers of “secondary”
cardiac hypertrophy, such as skeletal alpha-actin, isoforms
of myosin light chain and, less commonly, brain natriuretic
factor, also known to be activated in pressure-overload
induced (secondary) cardiac hypertrophy. Many of the
upregulated genes have not been previously implicated in
cardiac hypertrophy, and function of a few, such as sarcosin
(7) and SLIM1 (8), is unknown. In addition, structure and
function of proteins encoded by HSPC040 (9) and C1ORF8
(10), which have been identified by expressed sequence tags
analysis and comparative proteomics, respectively, are un-
known. Among the genes with the highest upregulation
were HSPA8, also known as HSP73, which is a member of
HSP70 multigene family with chaperoning roles for nascent
polypeptide facilitating their correct folding, translocation
and degradation (11). Expression of NDUFB10 encoding
for the first enzyme complex in the electron transport chain
of mitochondria (12) was also upregulated significantly.
Upregulation of the expression of HSPA8 and NDUFB10
(12), along with increased expression of many ribosomal
proteins is in accord with the increased protein synthesis
and mitochondria function in hypertrophic states and sig-
nifies their role as potential modulators of cardiac phenotype
in HCM. Other notable genes included GNAS1, encodes
for the GTP-binding protein Gs and couples the hormone-
receptor binding to adenylyl cyclase activation (13); VDAC1,
encodes for VDAC1 that forms the major pathway for
movement of adenine nucleotides through the outer mem-
brane of mitochondria (14) and sodium hydrogen ex-
changer, which is a ubiquitous membrane-bound enzyme
involved in pH regulation and activated by a variety of
signals including growth factors (15).
In summary, we have identified a variety of genes that are
upregulated in human patients with HCM that could
contribute to the diversity of clinical and pathologic pheno-
types of HCM. Increased expression of genes encoding for
the markers of “secondary” cardiac hypertrophy supports the
hypothesis that hypertrophy in HCM, a genetic disease, is
also a “secondary” phenotype and involves pathways that are
similar to those implicated in the acquired forms. Charac-
terization of the role of upregulated gene in HCM could
provide clues to the diversity of clinical and pathologic
phenotypes and for new therapeutic and preventive targets.
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